Low opsonic activity to the infecting serotype in pediatric patients with invasive pneumococcal disease

Vaccine

Volumn 31, Issue 5, 2013, Pages 845-849

  Oishi, Tomohiro ^a   Ishiwada, Naruhiko ^b   Matsubara, Kousaku ^c   Nishi, Junichiro ^d   Chang, Bin ^g   Tamura, Kazuyo ^e   Akeda, Yukihiro ^e   Ihara, Toshiaki ^f   Nahm, Moon H ^h   Oishi, Kazunori ^e,g  

^a NIIGATA UNIVERSITY MEDICAL AND DENTAL HOSPITAL   (Japan)

^b CHIBA UNIVERSITY   (Japan)

^c NISHI KOBE MEDICAL CENTER   (Japan)

^d KAGOSHIMA UNIVERSITY   (Japan)

^e OSAKA UNIVERSITY   (Japan)

^f MIE NATIONAL HOSPITAL   (Japan)

^g NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^h UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Children; Invasive pneumococcal disease; Opsonophagocytic activity; Pneumococcal vaccine; Serotype specific IgG

Indexed keywords

IMMUNOGLOBULIN G; OPSONIN; PNEUMOCOCCUS VACCINE;

ANTIGEN SPECIFICITY; ARTICLE; BACTERIAL IMMUNITY; BINDING AFFINITY; BLOOD SAMPLING; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; INFANT; INFECTION PREVENTION; JAPANESE; MALE; OPSONIZATION; PNEUMOCOCCAL INFECTION; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SEROTYPE;

ANTIBODIES, BACTERIAL; ANTIBODY AFFINITY; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNOGLOBULIN G; INFANT; MALE; OPSONIN PROTEINS; PNEUMOCOCCAL INFECTIONS; STREPTOCOCCUS PNEUMONIAE;

EID: 84872616875     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.11.010     Document Type: Article

References (25)

1. O'Brien K.L., Wolfsan L.J., Watt J.P., Henkle E., Deloria-Knoll M., McCall N., et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 2009, 374:893-902.
2. Musher D.M., Chapman A.J., Goree A., Jonsson S., Briles D., Baughn R.E. Natural and vaccine-related immunity to Streptococcus pneumoniae. J Infect Dis 1986, 154:245-256.
3. American Academy of Pediatrics; Committee on Infectious Diseases Policy statement: recommendations for the prevention of pneumococcal infections, including the use of pneumococcal conjugate vaccine (Prevnar), pneumococcal polysaccharide vaccine, and antibiotic prophylaxis. Pediatrics 2000, 106:362-366.
4. Whitney C.G., Farley M.M., Halder J., Harrison K.H., Bennet N.M., Lynfield R., et al. Decline in invasive pneumococcal disease following the introduction of protein polysaccharide conjugate vaccine. N Eng J Med 2003, 348:1737-1746.
5. O'Brien K.L., Moulton L.H., Reid R., Weatherholtz R., Oski J., Brown L., et al. Efficacy and safety of seven-valent conjugate vaccine in American Indian children: group randomized trial. Lancet 2003, 362:355-361.
6. Pilishvili T., Lexau C., Farley M.M., Hadler L.H., Bennett N.M., Reingold A., et al. Sustained reductions in invasive pneumococcal disease in era of conjugate vaccine. J Infect Dis 2010, 201:32-41.
7. Ishiwada N., Infection J., Ishiwada N., Kurosaki T., Terashima I., Khno Y., et al. The incidence of pediatric invasive pneumococcal disease in Chiba prefecture, Japan (2003-2005). J Infect 2008, 57:455-458.
8. O'Brien K.L., Shaw J., Weatherholtz R., Reid R., Watt J., Croll J., et al. Epidemiology of invasive Streptococcus pneumoniae among Navajo children in the era before of conjugate pneumococcal vaccine, 1989-1996. Am J Epidemiol 2004, 160:270-278.
9. Concepcion N.F., Frasch C.E. Pneumococcal type 22F polysaccharide absorption improves the specificity of a pneumococcal-polysaccharide enzyme-linked immunosorbent assay. Clin Diagn Lab Immunol 2001, 8:266-272.
10. Burton R.L., Nahm M.H. Development and validation of a fourfold multiplexed opsonization assay (MOPA4) for pneumococcal antibodies. Clin Vaccine Immunol 2006, 13:1004-1009.
11. World Health Organization Pneumococcal conjugate vaccines. Recommendations for the production and control of pneumococcal conjugate vaccines. WHO Tech Rep Ser 2005, 927(annex 2):64-98.
12. Henckaerts I., Goldblatt D., Ashton L., Poolman J. Critical differences between pneumococcal polysaccharide enzyme-linked immunosorbent assays with and without 22F inhibition at low antibody concentrations in pediatric sera. Clin Vaccine Immunol 2006, 13:356-360.
13. Henchkerts I., Durant N., De Grave D., Schuerman L., Poolman J. Validation of a routine opsonophagocytosis assay to predict invasive pneumococcal disease efficacy of conjugate vaccine in children. Vaccine 2007, 25:2518-2527.
14. Schuerman L., Wysocki J., Tejedor J.C., Knuf M., Kim K.H., Poolman J. Prediction of pneumococcal conjugate vaccine effectiveness against invasive pneumococcal disease using opsonophagocytic activity and antibody concentrations determined by enzyme-linked immunosorbent assay with 22F adsorption. Clin Vaccine Immunol 2011, 18:2161-2167.
15. Chang B., Otsuka T., Iwaya A., Okazaki M., Matsunaga S., Wada A. Isolation of Streptococcus pneumoniae serotypes 6C and 6D from the nasopharyngeal mucosa of healthy Japanese children. Jap J Infect Dis 2010, 63:381-383.
16. Wernette C.M., Frasch C.E., Madore D., Carlone G., Glodblatt D., Plikaytis B., et al. Enzyme-linked immunosorbent assay for quantitation of human antibodies to pneumococcal polysaccharides. Clin Vaccine Immunol 2003, 10:514-519.
17. Anttila M., Eskola J., Ahman H., Kayhty H. Avidity of IgG for Streptococcus pneumoniae type 6B and 23F polysaccharides in infants primed with pneumococcal conjugates and boosted with polysaccharide or conjugate vaccines. J Infect Dis 1998, 177:1614-1621.
18. Park S.Y., Van Beneden C.A., Pilishvili T., Martin M., Facklam R.R., Whitney C.G., et al. Invasive pneumococcal infections among vaccinated children in the United States. J Pediatr 2010, 156:478-483.
19. Centers for Disease Control and Prevention Advisory Committee on Immunization Practices (ACIP), updated recommendation from the Advisory Committee on Immunization Practices (ACIP) for use of 7-valent pneumococcal conjugate vaccine (PCV7) in children aged 24-59 months who are not completely vaccinated. MMWR Morb Mortal Wkly Rep 2008, 57:343-344.
20. Soininen A., Karpala M., Wahlman S.-L., Lehtonen H., Kayhty H. Specificities and opsonophagocytic activities of antibodies to pneumococcal capsular polysaccharide in sera of unimmunized young children. Clin Diag Lab Immunol 2002, 9:1032-1038.
21. Nuorti J.P., Whitney C.G. Centers for Disease Control and Prevention (CDC), prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2010, 59(RR-11):1-18.
22. 197 in United States infants. Pediatrics 1998, 101:606-611.
23. Usinger W.R., Locas A.H. Avidity as a determinant of the protective efficacy of human antibodies to pneumococcal capsular polysaccharides. Infect Immun 1999, 67:2366-2370.
24. Romero-Steiner S., Musher D.M., Cetron M.S., Pais L.B., Groover J.E., Fiore A.E., et al. Reduction in functional antibody activity against Streptococcus pneumoniae in vaccinated elderly individuals highly correlates with decreased IgG antibody avidity. Clin Infect Dis 1999, 29:281-288.
25. O'Brien K.L., Moisi J., Romero-Steiner S., Holder P., Carlone G.M., Reid R., et al. Pneumococcal antibodies in a child with type 14 pneumococcal conjugate vaccine failure. Vaccine 2009, 27:1863-1868.